0 15 Acetylsalicylic acetylsalicylic JJ 16 20 acid acid NN 21 24 and and CC 25 31 sodium sodium NN 32 42 salicylate salicylate NN 43 50 inhibit inhibit VBP 51 62 LPS-induced lps-induced JJ 63 71 NF-kappa NF-kappa NNP 72 79 B/c-Rel B/c-Rel NNP 80 87 nuclear nuclear JJ 88 101 translocation translocation NN 101 102 , , , 103 106 and and CC 107 116 synthesis synthesis NN 117 119 of of IN 120 126 tissue tissue NN 127 133 factor factor NN 134 135 ( ( ( 135 137 TF TF NNP 137 138 ) ) ) 139 142 and and CC 143 148 tumor tumor NN 149 157 necrosis necrosis NN 158 164 factor factor NN 165 169 alfa alfa NN 170 171 ( ( ( 171 180 TNF-alpha TNF-alpha NNP 180 181 ) ) ) 182 184 in in IN 185 190 human human JJ 191 200 monocytes monocyte NNS 200 201 . . . 203 205 We we PRP 206 210 have have VBP 211 223 investigated investigate VBN 224 227 the the DT 228 235 effects effect NNS 236 238 of of IN 239 254 acetylsalicylic acetylsalicylic JJ 255 259 acid acid NN 260 263 and and CC 264 270 sodium sodium NN 271 281 salicylate salicylate NN 282 284 on on IN 285 288 the the DT 289 300 LPS-induced lps-induced JJ 301 310 synthesis synthesis NN 311 313 of of IN 314 317 the the DT 318 331 pro-coagulant pro-coagulant JJ 332 339 protein protein NN 340 346 tissue tissue NN 347 353 factor factor NN 354 355 ( ( ( 355 357 TF TF NNP 357 358 ) ) ) 359 362 and and CC 363 366 the the DT 367 383 pro-inflammatory pro-inflammatory JJ 384 391 protein protein NN 392 397 tumor tumor NN 398 406 necrosis necrosis NN 407 419 factor-alpha factor-alpha NN 420 421 ( ( ( 421 430 TNF-alpha TNF-alpha NNP 430 431 ) ) ) 431 432 , , , 433 435 as as RB 436 440 well well RB 441 443 as as IN 444 447 the the DT 448 461 prostaglandin prostaglandin NN 462 466 PGE2 pge2 NN 467 469 in in IN 470 475 human human JJ 476 485 monocytes monocyte NNS 485 486 . . . 487 491 Both both DT 492 497 drugs drug NNS 498 514 dose-dependently dose-dependently RB 515 524 inhibited inhibit VBD 525 536 LPS-induced lps-induced JJ 537 539 TF TF NNP 540 543 and and CC 544 553 TNF-alpha TNF-alpha NNP 554 563 synthesis synthesis NN 564 566 at at IN 567 570 the the DT 571 575 mRNA mRNA NNP 576 579 and and CC 580 583 the the DT 584 591 protein protein NN 592 597 level level NN 597 598 , , , 599 602 and and CC 603 610 reduced reduce VBD 611 615 PGE2 pge2 NN 616 626 production production NN 626 627 . . . 628 630 As as IN 631 640 evidenced evidence VBN 641 643 by by IN 644 651 electro electro NN 652 660 mobility mobility NN 661 666 shift shift NN 667 672 assay assay NN 673 674 ( ( ( 674 678 EMSA EMSA NNP 678 679 ) ) ) 680 683 and and CC 684 687 the the DT 688 691 use use NN 692 694 of of IN 695 696 a a DT 697 705 NF-kappa NF-kappa NNP 706 707 B B NNP 708 718 prototypic prototypic JJ 719 724 probe probe NN 724 725 , , , 726 731 these these DT 732 737 drugs drug NNS 738 746 probably probably RB 747 752 exert exert VBP 753 758 their their PRP$ 759 769 inhibitory inhibitory JJ 770 777 effects effect NNS 778 780 by by IN 781 793 interference interference NN 794 798 with with IN 799 802 the the DT 803 810 nuclear nuclear JJ 811 824 translocation translocation NN 825 827 of of IN 828 836 NF-kappa NF-kappa NNP 837 844 B/c-Rel B/c-Rel NNP 845 853 proteins protein NNS 853 854 . . . 855 860 These these DT 861 865 data datum NNS 866 869 may may MD 870 876 expand expand VB 877 880 the the DT 881 894 understanding understanding NN 895 897 of of IN 898 901 the the DT 902 917 anti-thrombotic anti-thrombotic JJ 918 921 and and CC 922 939 anti-inflammatory anti-inflammatory JJ 940 947 effects effect NNS 948 950 of of IN 951 956 these these DT 957 962 drugs drug NNS 963 967 when when WRB 968 978 activation activation NN 979 981 of of IN 982 991 monocytes monocyte NNS 992 998 occurs occur VBZ 998 999 . . .